About Greg

Greg Perry joined the Medicines Patent Pool (MPP) as Executive Director in January 2013, bringing more than 20 years of experience in pharmaceuticals, intellectual property and healthcare policy to the foundation. Prior to his role at the MPP, he served as Founding Director and later Director General of the European Generic Medicines Association. He also was a founding member of the International Generic Pharmaceutical Alliance. Previously he worked as a European Union policy advisor to corporate as well as non-governmental organisations and prior to that as parliamentary advisor to Members of the European Parliament. In 2004, he was awarded the Golden Cross of Merit of the Republic of Poland for his contribution to industry and European integration, one of a few non-Polish nationals to be honoured with this distinction. Perry was a member of the Standing Advisory Committee before the European Patent Office (SACEPO) for five years and is currently an Honorary Life Fellow of the Organisation for Professionals in Regulatory Affairs in the United Kingdom (TOPRA) UK. Under his direction, the MPP launched new licensing agreements to improve access to HIV, hepatitis C and tuberculosis treatments in developing countries.

This speaker will be presenting at the following session(s)

  • Access to treatment


    Day: 2 November

    Time: 15:30

    This closing panel session examines how to develop the uninterrupted supply of quality-assured vaccines, medicines, diagnostics and other commodities on which effective hepatitis programmes are dependent.

    Chair: Liudmyla Maistat, Medicines Patent Pool

    Chair: Charles Gore, World Hepatitis Alliance


    • Introduction to Intellectual Property.
    • Ellen ‘t Hoen, University Medical Centre Groningen
    • Patent opposition.
    • Direct price negotiations.
    • Compulsory licensing.
    • Voluntary licensing.
    • Greg Perry, Medicines Patent Pool
    • Open discussion with audience.


    • To provide an overview of key IP barriers to access hepatitis C treatment.
    • To review different approaches to overcoming price and IP barriers and the progress made.
    • To discuss the possibility for organisations and civil society groups applying different methods and approaches to scaling up access to hepatitis C treatment to be complementary in their strategies.